A decision on tolebrutinib for treating MS is now set for Sept. 28, after the FDA granted priority review to its approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback